Publicacións en colaboración con investigadores/as de Hospital Universitario Son Espases (10)

2024

  1. Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis

    Journal of Medical Economics, Vol. 27, Núm. 1, pp. 1379-1387

2023

  1. The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study

    Cancers, Vol. 15, Núm. 11

2022

  1. SEOM-GEICO clinical guidelines on endometrial cancer (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 625-634

2021

  1. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

    BMC Cancer, Vol. 21, Núm. 1

2020

  1. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

    Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148

2018

  1. Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain

    Psycho-Oncology, Vol. 27, Núm. 6, pp. 1530-1537

2014

  1. Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: Results from a 2-year multicentre observational study (ZOMAR study)

    Bone, Vol. 68, pp. 32-40

2012

  1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246

2009

  1. Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial

    Breast Cancer Research and Treatment, Vol. 116, Núm. 2, pp. 351-358

2008

  1. A single-nucleotide polymorphismin the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma

    Clinical Cancer Research, Vol. 14, Núm. 3, pp. 811-816